| Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations M Dankner, AAN Rose, S Rajkumar, PM Siegel, IR Watson Oncogene 37 (24), 3183-3199, 2018 | 406 | 2018 |
| Single-cell spatial immune landscapes of primary and metastatic brain tumours E Karimi, MW Yu, SM Maritan, LJM Perus, M Rezanejad, M Sorin, ... Nature 614 (7948), 555-563, 2023 | 107 | 2023 |
| CEACAM1 as a multi-purpose target for cancer immunotherapy M Dankner, SD Gray-Owen, YH Huang, RS Blumberg, N Beauchemin Oncoimmunology 6 (7), e1328336, 2017 | 106 | 2017 |
| Spatially mapping the immune landscape of melanoma using imaging mass cytometry D Moldoveanu, LA Ramsay, M Lajoie, L Anderson-Trocme, M Lingrand, ... Science immunology 7 (70), eabi5072, 2022 | 69 | 2022 |
| Dual MAPK inhibition is an effective therapeutic strategy for a subset of class II BRAF mutant melanomas M Dankner, M Lajoie, D Moldoveanu, TT Nguyen, P Savage, S Rajkumar, ... Clinical Cancer Research 24 (24), 6483-6494, 2018 | 67 | 2018 |
| STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancer SP Totten, YK Im, E Cepeda Cañedo, O Najyb, A Nguyen, S Hébert, ... Nature Communications 12 (1), 3299, 2021 | 38 | 2021 |
| Chemogenomic profiling of breast cancer patient-derived xenografts reveals targetable vulnerabilities for difficult-to-treat tumors P Savage, A Pacis, H Kuasne, L Liu, D Lai, A Wan, M Dankner, ... Communications biology 3 (1), 310, 2020 | 31 | 2020 |
| Clinical activity of mitogen-activated protein kinase–targeted therapies in patients with non–V600 BRAF-mutant tumors M Dankner, Y Wang, R Fazelzad, B Johnson, CA Nebhan, I Dagogo-Jack, ... JCO Precision Oncology 6, e2200107, 2022 | 24 | 2022 |
| Invasive growth associated with Cold-Inducible RNA-Binding Protein expression drives recurrence of surgically resected brain metastases M Dankner, M Caron, T Al-Saadi, WQ Yu, V Ouellet, R Ezzeddine, ... Neuro-oncology 23 (9), 1470-1480, 2021 | 24 | 2021 |
| Targeted therapy for colorectal cancers with non-V600 BRAF mutations: perspectives for precision oncology M Dankner JCO Precision Oncology 2, 1-12, 2018 | 20 | 2018 |
| p66ShcA functions as a contextual promoter of breast cancer metastasis K Lewis, A Kiepas, J Hudson, J Senecal, JR Ha, E Voorand, MG Annis, ... Breast Cancer Research 22, 1-19, 2020 | 19 | 2020 |
| The underlying biology and therapeutic vulnerabilities of leptomeningeal metastases in adult solid cancers M Dankner, S Lam, T Degenhard, L Garzia, MC Guiot, K Petrecca, ... Cancers 13 (4), 732, 2021 | 18 | 2021 |
| Melanomas with concurrent BRAF non-p. V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy S Rajkumar, D Berry, KA Heney, C Strong, LA Ramsay, M Lajoie, ... Cell Reports 39 (1), 2022 | 14 | 2022 |
| DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy C Bernier, A Soliman, M Gravel, M Dankner, P Savage, K Petrecca, ... Anti-Cancer Drugs 29 (8), 774-785, 2018 | 14 | 2018 |
| Radiomics as an emerging tool in the management of brain metastases A Nowakowski, Z Lahijanian, V Panet-Raymond, PM Siegel, K Petrecca, ... Neuro-Oncology Advances 4 (1), vdac141, 2022 | 9 | 2022 |
| Post‐mortem tissue donation programs as platforms to accelerate cancer research M Dankner, B Issa‐Chergui, N Bouganim The Journal of Pathology: Clinical Research 6 (3), 163-170, 2020 | 9 | 2020 |
| CCN3/nephroblastoma overexpressed is a functional mediator of prostate cancer bone metastasis that is associated with poor patient prognosis M Dankner, V Ouellet, L Communal, E Schmitt, D Perkins, MG Annis, ... The American Journal of Pathology 189 (7), 1451-1461, 2019 | 9 | 2019 |
| Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases AM Lazaratos, SM Maritan, A Quaiattini, A Darlix, I Ratosa, E Ferraro, ... The Breast, 2023 | 7 | 2023 |
| Non-small-cell lung cancer: how to manage BRAF-mutated disease G Guaitoli, L Zullo, M Tiseo, M Dankner, AAN Rose, F Facchinetti Drugs in Context 12, 2023 | 7 | 2023 |
| An exercise in scientific writing for physicians in training HT Whittaker, L Skerritt, M Dankner, MJ Eisenberg Clinical and Investigative Medicine 43 (1), E35-E38, 2020 | 7 | 2020 |
